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ABSTRACT
Objectives: This study aimed to determine the
presence of spin in papers on positive randomised
clinical trials (RCTs) of antidepressant medication for
anxiety disorders by comparing concerns expressed in
the Food and Drug Administration (FDA) reviews with
those expressed in the published paper.
Methods: For every positive anxiety medication trial
with a matching publication (n=41), two independent
reviewers identified the concerns raised in the US FDA
reviews and those in the published literature. Spin was
identified when concerns or limitations were expressed
by the FDA (about the efficacy of the study drug) but
not in the corresponding published paper. Concerns
mentioned in the papers but not by the FDA were
scored as ‘non-FDA’ concerns.
Findings: Only six out of 35 (17%) of the FDA
concerns pertaining to drug efficacy were reported in
the papers. Two papers mentioned a concern that fit
the FDA categories, but was not mentioned in the
corresponding FDA review. Eighty-seven non-FDA
concerns were counted, which often reflected general
concerns or concerns related to the study design.
Conclusions: Results indicate the presence of
substantial spin in the clinical trial literature on drugs
for anxiety disorders. In papers describing RCTs on
anxiety medication, the concerns raised by the authors
differed from those raised by the FDA. Published
papers mentioned a large number of generic concerns
about RCTs, such as a lack of long-term research and
limited generalisability, while they mentioned few
concerns about drug efficacy. These results warrant the
promotion of independent statistical review, reporting
of patient-level data, more study of spin, and an
increased expectation that authors report FDA
concerns.
INTRODUCTION
It is becoming increasingly apparent that the
results of scientiﬁc research are not always
accurately reported. Results are frequently
presented more positively than they actually
are.1 2 For example, trials are more likely to
be published if they are positive, and authors
may selectively report outcome measures in
such a way that negative trials appear posi-
tive.3–7 Reporting strategies, intentional or
unintentional, which mislead readers in their
evaluation of the beneﬁcial effects of ex-
perimental interventions or their safety, are
called ‘spin’.8 9 Examples include the overin-
terpretation of results10 and exaggerated
claims in press releases and media coverage
of studies.11
Although awareness of spin is increasing,
most studies of spin in the scientiﬁc litera-
ture have focused on randomised clinical
trials (RCTs) whose primary outcomes are
negative.7 8 12–16 However, the fact that a
primary outcome is positive does not preclude
spin.11 Researchers might, for example,
emphasise the most favourable-looking vari-
able or manipulate ﬁgures.3 5 16 In papers
about RCTs with positive primary outcomes,
the most prominent types of spin are arguably
the exaggeration of drug efﬁcacy and con-
cerns regarding trial outcome reliability.
Strengths and limitations of this study
▪ Novel study of spin regarding efficacy-related
concerns in drug randomised clinical trials with
positive primary outcomes.
▪ Food and Drug Administration (FDA) reviews are
used as an objective source to compare with the
published literature.
▪ The estimate may be conservative because FDA
concerns required agreement between FDA
reviewers, which was not always the case.
▪ No other types of spin were examined.
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Examples include when the study drug had no effect on
secondary end points or when drug efﬁcacy was shown
only for men or only for women. Treatment decisions are
inﬂuenced by the way such concerns are presented.
One way to detect spin in publications on positive
trials is to compare the concerns raised about a medica-
tion trial in the reporting paper with those reported by
an objective, independent third party. The US Food and
Drug Administration (FDA) can play such a role. Before
a drug can be marketed in the USA, it must be approved
by the FDA. Before starting any US trial, pharmaceutical
companies must notify the FDA of its details, such as
the primary end point and statistical analytic method.
When the trial is completed, FDA medical and statistical
reviewers inspect the sponsor’s results, trying to replicate
them using the patient-level data submitted by the
sponsor. The reviewers then write a summary report on
each of the trials, together with a recommendation as to
whether the drug meets the FDA’s criteria for marketing
approval. These reports are examined by higher level
reviewers (team leader, division director, sometimes
ofﬁce director), culminating in the decision whether to
approve the drug.17 These reports are combined into an
FDA drug approval package (hereafter called FDA
review), which is made publicly available.18 The exist-
ence of multiple reviews increases the odds that any con-
cerns regarding drug efﬁcacy results will be expressed.
Spin can be measured by comparing concerns men-
tioned in the FDA drug approval packages with those
mentioned in corresponding trial publications.
The objective of this study is to examine spin in the
reporting of positive RCTs of antidepressant medication
for anxiety disorders, by comparing concerns expressed




In a previous paper, Roest et al7 identiﬁed a cohort of
phase 2 and 3 double-blind placebo-controlled clinical
trials that had been registered with the FDA in pursuit
of marketing approval; the drugs were second-
generation antidepressants for the treatment of ﬁve
anxiety disorders (generalised anxiety disorder, panic
disorder, social anxiety disorder, post-traumatic stress dis-
order and obsessive-compulsive disorder). Nine drugs
were approved for these indications by the FDA: seven
selective serotonin reuptake inhibitors (SSRIs): paroxe-
tine, paroxetine controlled release, sertraline, ﬂuoxet-
ine, ﬂuvoxamine, ﬂuvoxamine controlled release and
escitalopram, and two serotonin norepinephrine re-
uptake inhibitors (SNRIs): venlafaxine extended release
and duloxetine. FDA reviews were downloaded from the
FDA’s website (http://www.accessdata.fda.gov/scripts/
cder/drugsatfda/index.cfm), or, if these reviews were
not available for download, requested from the FDA’s
Freedom of Information Ofﬁce (http://www.accessdata.
fda.gov/scripts/foi/FOIRequest/requestinfo.cfm). The
reader may access these reviews at http://doi.org/10.
6083.M4H9949P.
In that previous paper, the FDA’s regulatory decisions
were previously classiﬁed as (1) positive (clearly support-
ing efﬁcacy) or (2) not positive.7 The current study
included only positive trials (κ=41), that is, trials with
statistically signiﬁcant results on the primary end point
(s). Since the FDA review for ﬂuoxetine in the treat-
ment of panic disorder became available after the publi-
cation of Roest et al, this study was able to include one
additional positive trial. These 42 trials were covered in
21 FDA reviews (one for each drug indication
combination, each including 1–4 trials) (see ﬁgure 1).
Further details on the number of trials included in each
FDA review can be found in supplementary Table 1 of
Roest et al.7
Published papers
Matching journal publications for the 41 trials were
identiﬁed, as reported in Roest et al,7 by systematically
searching PubMed, EMBASE and the Cochrane Central
Register of Controlled Trials without language restric-
tions, with a search cut-off date of 19 December 2012.
The title ﬁeld was searched for the name of the drug and
the type of anxiety disorder and any ﬁeld was searched
for the word placebo. The matching paper for the add-
itional (ﬂuoxetine) trial included in this study was found
by hand search. One trial was not published. The other
41 trials were described in 38 papers because six trials
were published in pooled analyses (see ﬁgure 1).
Concerns
For each trial with a matching publication (κ=41), we
scored concerns in that publication and in the FDA
review. A concern was deﬁned as an expressed limitation
Figure 1 Flow chart of trial and paper selection.
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regarding a speciﬁc trial. Two independent researchers
(AMR and LB) ﬁrst scored concerns expressed in the
FDA reviews. Subsequently, the concerns in the papers
were scored independently by researchers LB and
BFJ. Discrepancies were resolved by consensus (LB, BFJ,
AMR). The inter-rater agreement was expressed in terms
of Cohen’s κ, which, following Landis and Koch,19 is
regarded as moderate from 0.41 to 0.60, substantial
from 0.61 to 0.80 and almost perfect above 0.81.
Concerns in the FDA reviews
Concerns in the FDA reviews were counted when they
were expressed by at least two FDA parties (eg, medical
reviewer, statistical reviewer, team leader, division dir-
ector). Only in exceptional cases were concerns counted
when they were mentioned only by the medical reviewer:
(1) when the statistical review was missing and the
concern was also reported in other FDA reviews, or (2)
when no detailed evaluation on a speciﬁc trial was
present for the statistical reviewer and team leader. The
concerns found in the FDA reviews were sorted into 11
categories (ﬁgure 2).
Concerns in the papers
The FDA concerns were counted as present or absent in
the abstract or discussion section of each paper.
Additionally, since FDA concerns might not be the only
relevant ones, concerns mentioned in the papers but
not by the FDA were scored as ‘non-FDA’ concerns and
grouped into categories (see ﬁgure 3). Concerns in the
papers were counted when they were either mentioned
in the limitations section or clearly formulated as a
concern. This included any formulation that contained
signal words like ‘unfortunately’ or ‘cause for concern’,
or was framed as a future research question.
Spin
Spin was identiﬁed when concerns about drug efﬁcacy




A total of 38 concerns were identiﬁed in the 41 trials
(89% directly, the rest after debate). Inter-rater reliability
was substantial (κ=0.73). Eleven of these concerns per-
tained to the lack of evidence for a dose–response rela-
tionship. The second and third largest categories of
concerns pertained to the lack of statistical signiﬁcance
on the primary end point(s) according to the observed
cases (OC) and last observation carried forward (LOCF)
analyses, respectively. The other categories occurred
only one to three times (see ﬁgure 2), but these were
more serious concerns, including lack of efﬁcacy in one
of the sexes, lack of signiﬁcant ﬁndings for all dose
groups and a lower efﬁcacy of the study drug compared
with previously approved drugs.
Paper concerns
In our review of the 38 papers, we identiﬁed a total of
86 concerns (62%) directly; the rest were debated (inter-
rater reliability substantial, κ=0.64). Almost all (99%)
concerns were mentioned in the discussion paragraph
of the paper. Four of these concerns were also men-
tioned in the abstract. One concern occurred in the
abstract but not in the discussion section of the paper.
Spin in the papers
In three instances, one FDA concern was present for
both trials published in pooled analyses. To keep the
comparison between FDA and paper concerns
Figure 2 FDA concerns in FDA review packages and related trial papers. *In specific cases, the FDA allowed for multiple
primary end points. +Such that the FDA excluded results from analysis. FDA, Food and Drug Administration.
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conservative, such a pair was counted as a single FDA
concern, leaving 35 unique concerns. Only six of these
35 (17%) FDA concerns were found in the trial papers
(covering three categories), as outlined in ﬁgure 2. The
concern category most frequently present in the papers
was the lack of a dose–response relationship (four cases
in papers vs 11 in FDA reviews). Two papers mentioned
a concern that ﬁt the FDA categories, but was not men-
tioned in the corresponding FDA review (not shown in
ﬁgure 2). These concerns pertained to the lack of a
dose–response relationship and the lack of signiﬁcance
in OC analyses.
Non-FDA concerns in the papers
Six of the concerns mentioned in the papers were also
scored by the FDA (7%), and two concerns from the
papers fell into the FDA categories. This left 78 add-
itional concerns not mentioned by the FDA, yielding an
average of two concerns per reviewed paper. As can be
seen in ﬁgure 3, the most abundant of the concerns not
mentioned by the FDA pertained to the lack of long-
term research (68% of papers). The second most
common concern focused on the lack of generalisability,
usually due to study exclusion criteria. Fourteen con-
cerns occurred only once and were scored as ‘other’
concerns.
DISCUSSION
This paper demonstrates, within a cohort of positive
RCTs for anxiety disorders, the existence of spin. The
FDA commonly expressed concerns about drug efﬁcacy,
but only a fraction of these (17%) were conveyed in the
corresponding journal publications. The published
papers mentioned 12 times more non-FDA concerns
(n=78) than FDA concerns (n=6), but the former
consisted largely of generic concerns applicable to virtu-
ally any RCT, such as a lack of long-term research and
limited trial generalisability. Other non-FDA concerns
often reﬂected design choices, such as lack of an active
comparator. Publication of such generic concerns, when
coupled with a lack of stated concerns about drug efﬁ-
cacy, could itself be interpreted as a type of spin.
Strengths and limitations
The results of this study should be interpreted in the
light of the following strengths and limitations. Our def-
inition of spin excluded other types of spin, for
example, linguistic spin5 and graphical misrepresenta-
tion of data,3 so this study arguably presents an overly
conservative picture. Nonetheless, we feel that misrepre-
sentation of concerns about drug efﬁcacy, in the context
of RCTs with positive results, may be a more important
type of spin because of its more direct relevance to clin-
ical practice. Failure to transparently convey efﬁcacy con-
cerns might distort the drug’s apparent risk–beneﬁt
ratio, leading to undue clinician enthusiasm and poten-
tially inappropriate treatment.
The strength of the study lies in our having under-
taken a straightforward comparison using an objective
third party. However, we cannot be sure that the FDA
reviews included mention of all relevant concerns about
drug efﬁcacy, hence our search for concerns in pub-
lished papers. Also, while the FDA reviewers are object-
ive third-party evaluators of drug efﬁcacy, they did not
always report the same concerns. For example, high
dropout rates, an issue sometimes mentioned by statis-
tical reviewers, was never raised by medical reviewers or
team leaders. Our requirement that speciﬁc FDA con-
cerns be expressed in two or more reviews might have
led to an underestimation of the total number of FDA
Figure 3 Non-FDA concerns in trial papers. *Concerns that occurred only once were classified as ‘Other. FDA, Food and Drug
Administration.
4 Beijers L, et al. BMJ Open 2017;7:e012886. doi:10.1136/bmjopen-2016-012886
Open Access
group.bmj.com on April 5, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
concerns. Finally, a minority of the publications pre-
ceded (rather than followed) the FDA approval date,
leaving open the possibility that the FDA had not yet
made the sponsor aware of its efﬁcacy concerns, which
could explain the sponsor’s not mentioning them in the
paper. However, our aim was not to ascertain whether
authors conveyed concerns expressed to them by the
FDA, but rather whether they had thoughtfully reﬂected
on their trial’s limitations and conscientiously reported
them.
Implications
We observed that most FDA concerns about drug
efﬁcacy were not mentioned in trial papers, whereas
most non-FDA concerns were vague and could apply to
virtually any clinical trial. While we agree that the lack
of long-term research is a problem, a plethora of
non-efﬁcacy-related concerns might serve to obfuscate
or distract from issues of greater relevance to clinicians.
This raises ethical questions, considering that problems
associated with prescription drug use (eg, poisoning)
are third on the list of causes of death in Europeans
and Americans above age 65, after heart disease and
cancer.1 20 21 Anxiety disorders have an estimated year
prevalence of 12% and antidepressants are the primary
pharmacological treatment for anxiety.21 About 10% of
Europeans currently use SSRIs or SNRIs on a daily
basis.22–24
Previous studies have shown that bias and spin occur in
many scientiﬁc ﬁelds.3 4 7 8 12–15 17 To further determine
the extent to which concerns about drug efﬁcacy are mis-
represented in published papers, the method employed
here can be applied to other ﬁelds. If misrepresentation
of concerns proves to be widespread, a number of mea-
sures can be taken. One possible approach is to have
patient-level data analysed and reviewed by an independ-
ent party, as has been carried out for at least one contro-
versial trial.25 26 Another is for journal reviewers and
editors to require authors of publications to mention
FDA concerns, though this could be carried out only for
studies published after FDA approval.
CONCLUSION
This study indicates that, in the context of anxiety medi-
cation trials with positive primary outcomes, published
papers substantially misrepresent concerns about drug
efﬁcacy. The majority of concerns raised by the FDA, an
independent third party, were not reported in matching
publications. The concerns raised in the papers by spon-
sors, who have a ﬁnancial interest in the outcome of the
trial, were often vague and applicable to clinical drug
trials in general. Such concerns may be overrepresented
at the expense of issues of greater importance to clini-
cians, such as (problems with) drug efﬁcacy.
Patient-level data reporting, independent review and
increased expectation that authors convey FDA concerns
could help reduce spin. Before such measures are
implemented, however, this phenomenon should be
investigated in related ﬁelds.
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